What does business segments — insurance and other mean?

Aggregate costs for insurance coverage and miscellaneous operational expenses attributable to the clinical development segment. This provides insight into the overhead required to mitigate operational risks in drug development.

Nuvectis Pharma, Inc. NVCT Business Segments — Insurance And Other

Similar metrics at other companies

BCAXReportable Segment — Clinical operations and development

$23.21M+24.4%

SRPTAll Other Segments — Clinical Trial Expenses

$18.3M-44.8%

RXRXReportable Segment — Clinical development

$6.57M-37.8%

RAPPOther Costs — Research And Development Expense

$1.97M+24.7%

GERNResearch and clinical expenses — R&D

$13M-5.1%

MPLTClinical Trial — Research And Development Expense

$24.82M+1,180%

Other financials

Income statement

See full

Operating income-$6.3M-12.4%

Net income-$6.1M-13.5%

EPS (diluted)-$0.26+3.7%

Balance sheet

See full

Cash & equivalents$25.1M-15.9%

Total equity$14.2M-32.1%

Total assets$25.4M-15.8%

Cash flow

See full

Operating cash flow-$6.5M-56.0%

Valuation

See full

Market cap$739.27M+335%

Returns & leverage

See full

Return on equity-154.4%+79.4pp

Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept nvct:InsuranceAndOther.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s business segments — insurance and other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s business segments — insurance and other?: Nuvectis Pharma, Inc. (NVCT) reported business segments — insurance and other of $396K in Q1 2026.
What does business segments — insurance and other mean?: Aggregate costs for insurance coverage and miscellaneous operational expenses attributable to the clinical development segment. This provides insight into the overhead required to mitigate operational risks in drug development.